Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies
The study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in English during 2001–2016 was done.AEFIs incidence (I) was estimated and compared between MenAfri...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-06-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2019.1652041 |
| _version_ | 1797677372585017344 |
|---|---|
| author | Jerome Ateudjieu Beat Stoll Anne Cecile Bisseck Ayok M. Tembei Blaise Genton |
| author_facet | Jerome Ateudjieu Beat Stoll Anne Cecile Bisseck Ayok M. Tembei Blaise Genton |
| author_sort | Jerome Ateudjieu |
| collection | DOAJ |
| description | The study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in English during 2001–2016 was done.AEFIs incidence (I) was estimated and compared between MenAfrivac™ clinical trials and immunization campaigns using incidence difference (Id). Nine studies were included with an overall local AEFI I of 11,496/100,000 doses administered per week in clinical trials and 0.72/100,000 doses in immunization campaigns. An Id of 11,497.92 [11,497.91-11,497.93] and 17,243.20 [17,241.80-17,245.90] per 100,000 doses administered per week for overall local and systemic AEFI, respectively, were observed with highest from clinical trials. The incidence of AEFIs after MenAfrivac™ vaccination was far lower in campaigns than in clinical trial studies. Current capacity of AEFI surveillance during vaccination campaigns requires extensive re-assessment of its structure and capacity. |
| first_indexed | 2024-03-11T22:44:07Z |
| format | Article |
| id | doaj.art-c91e35bdfdc146cfb84079dc8bf05c4e |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:07Z |
| publishDate | 2020-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-c91e35bdfdc146cfb84079dc8bf05c4e2023-09-22T08:45:33ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-06-011661245125910.1080/21645515.2019.16520411652041Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studiesJerome Ateudjieu0Beat Stoll1Anne Cecile Bisseck2Ayok M. Tembei3Blaise Genton4University of DschangUniversity of GenevaMinistry of Public HealthM.A. SANTE (Meileur Accès aux soins de santé)Swiss Tropical and Public Health InstituteThe study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in English during 2001–2016 was done.AEFIs incidence (I) was estimated and compared between MenAfrivac™ clinical trials and immunization campaigns using incidence difference (Id). Nine studies were included with an overall local AEFI I of 11,496/100,000 doses administered per week in clinical trials and 0.72/100,000 doses in immunization campaigns. An Id of 11,497.92 [11,497.91-11,497.93] and 17,243.20 [17,241.80-17,245.90] per 100,000 doses administered per week for overall local and systemic AEFI, respectively, were observed with highest from clinical trials. The incidence of AEFIs after MenAfrivac™ vaccination was far lower in campaigns than in clinical trial studies. Current capacity of AEFI surveillance during vaccination campaigns requires extensive re-assessment of its structure and capacity.http://dx.doi.org/10.1080/21645515.2019.1652041menafrivac™ safetyaefi surveillanceclinical trialsimmunization campaigns |
| spellingShingle | Jerome Ateudjieu Beat Stoll Anne Cecile Bisseck Ayok M. Tembei Blaise Genton Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies Human Vaccines & Immunotherapeutics menafrivac™ safety aefi surveillance clinical trials immunization campaigns |
| title | Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies |
| title_full | Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies |
| title_fullStr | Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies |
| title_full_unstemmed | Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies |
| title_short | Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies |
| title_sort | safety profile of the meningococcal conjugate vaccine menafrivac™ in clinical trials and vaccination campaigns a review of published studies |
| topic | menafrivac™ safety aefi surveillance clinical trials immunization campaigns |
| url | http://dx.doi.org/10.1080/21645515.2019.1652041 |
| work_keys_str_mv | AT jeromeateudjieu safetyprofileofthemeningococcalconjugatevaccinemenafrivacinclinicaltrialsandvaccinationcampaignsareviewofpublishedstudies AT beatstoll safetyprofileofthemeningococcalconjugatevaccinemenafrivacinclinicaltrialsandvaccinationcampaignsareviewofpublishedstudies AT annececilebisseck safetyprofileofthemeningococcalconjugatevaccinemenafrivacinclinicaltrialsandvaccinationcampaignsareviewofpublishedstudies AT ayokmtembei safetyprofileofthemeningococcalconjugatevaccinemenafrivacinclinicaltrialsandvaccinationcampaignsareviewofpublishedstudies AT blaisegenton safetyprofileofthemeningococcalconjugatevaccinemenafrivacinclinicaltrialsandvaccinationcampaignsareviewofpublishedstudies |